Media Centre

Home About Us Services Forsøgspersoner Media Centre Contact

> News

> Events

> Downloads

> Links

Seperator

News

Enrolment started in first‑in‑humans study (SIS‑01)

DanTrials has started the enrolment of healthy male and female subjects in a first‑in‑humans study (SIS‑01) investigating a new potential drug for the treatment of COVID-19.


Enrolment started in first‑in‑humans study (KBP‑336‑CD‑001)

DanTrials has started the enrolment of healthy young male subjects in a first‑in‑humans study (KBP‑336‑CD‑001) investigating a new potential drug for the treatment of obesity.


Results of first‑in‑humans study with antiviral candidate for treatment of COVID‑19 published

The results of a first-in-humans study conducted at DanTrials which investigated the safety and tolerability as well as pharmacokinetics of inhaled and intranasal niclosamide have recently been published in The Lancet Regional Health - Europe: A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19


Results of first‑in‑humans study in prostate cancer patients published

The results of a first‑in‑humans study conducted at DanTrials where prostate cancer patients were vaccinated against RhoC have recently been published in Journal for ImmunoTherapy of Cancer: Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial


Send an email to info@dantrials.com or give CEO Torben Balchen a call on (+45) 3135 2683 to learn more.


> To top of page

Seperator

Events

There are no events at the moment.

> To top of page

Seperator

Downloads

None available at the moment.

> To top of page

Seperator

Links

The Danish Medicines Agency

The National Committee on Health Research Ethics

The Danish Data Protection Agency

> To top of page

Vortexing af blodprøve